Background: Inflammatory bowel disease (IBD) is a chronic immune-related condition caused by interactions between genetics, immune dysfunction, gut microbiota changes, and environmental factors, often presenting as persistent or recurring diarrhea. Clinically, it commonly presents with chronic diarrhea and other gastrointestinal symptoms. The global prevalence of IBD is increasing, currently affecting approximately 0.5% of the population, with projections suggesting a rise to nearly 1% by 2030. Fecal calprotectin is a neutrophil-derived S100 calcium-binding protein that is elevated in intestinal mucosal inflammation and serves as a reliable noninvasive biomarker of inflammatory activity. Due to its high stability and close association with intestinal inflammatory activity, fecal calprotectin has been established as a dependable, non-invasive marker for identifying intestinal inflammation. In clinical practice, it is extensively used to distinguish IBD from functional gastrointestinal disorders, especially irritable bowel syndrome, among patients presenting with chronic diarrhea. However, its diagnostic utility in Mongolia remains underexplored, and this study aims to determine its sensitivity and specificity in inflammatory bowel disease and compare its diagnostic performance with other inflammatory markers. Aim: To determine the sensitivity and specificity of fecal calprotectin in inflammatory bowel disease and to compare it with other inflammatory markers. Materials and Methods: A total of 109 participants aged 18-87 years with chronic diarrhea, who attended the gastroenterology outpatient clinics of the Mongolia–Japan Hospital and Intermed Hospital between December 2024 and December 2025 and provided informed consent, were enrolled in this study. Data were collected using structured questionnaires, and laboratory investigations included complete blood count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and measurement of fecal calprotectin levels from stool samples. Based on fecal calprotectin results, selected participants underwent colonoscopic examination as clinically indicated. Results: Among the 109 participants included in the study, 17.4% were diagnosed with inflammatory bowel disease (IBD), with a mean age of 47.41±15.52 years. Fecal calprotectin levels were significantly higher in the IBD group compared to the control group (p<0.001). Fecal calprotectin demonstrated a weak positive correlation with C-reactive protein (CRP) and leukocyte count (p=0.042, p=0.06), while no significant correlation was observed with erythrocyte sedimentation rate (ESR). At a cutoff value of 250 µg/g, fecal calprotectin showed a sensitivity of 94.4%, specificity of 69.2%, positive predictive value (PPV) of 37.8%, and negative predictive value (NPV) of 98.4%. Receiver operating characteristic (ROC) curve analysis identified an optimal cutoff value of approximately 400 µg/g (AUC=0.919, Youden index=0.724), at which the sensitivity remained 94.4% and specificity increased to 78.0%. In contrast, CRP and ESR demonstrated comparatively lower diagnostic performance, with AUC values of 0.640 and 0.644, respectively. Conclusion This study demonstrates that fecal calprotectin has superior diagnostic performance compared to conventional inflammatory markers in differentiating inflammatory bowel disease (IBD). An optimal cutoff value of approximately 400 µg/g yielded the highest sensitivity and specificity. Therefore, fecal calprotectin may serve as a valuable tool in clinical practice for both screening and diagnostic confirmation.

Background: Accreditation of healthcare institutions serves as a fundamental mechanism for ensuring patient safety and validating the quality of medical services provided to the population. At Intermed Hospital, a quality measurement system for healthcare services has been established since 2015, encompassing 126 quality indicators at both institutional and departmental levels. This system facilitates continuous quality improvement efforts. In this context, quality indicators specific to the endoscopy department play a pivotal role in objectively assessing the quality of endoscopic services. Aim: To assess the quality indicators in gastrointestinal endoscopy unit. Materials and Methods: A retrospective single-center study was conducted by collecting data from the Intermed hospital’s electronic information systems which included HIS and PACS and Quality and Safety Department’s Database and the results were processed using the SPSS software. Ethical approval was granted by the Intermed hospital’s Scientific research committee. The quality of endoscopic services in the Intermed hospital was assessed based on: a) the average values of four quality indicators measured monthly; b) sample survey data from five categories of quality indicators. Results : Between 2016 and 2024, the quality indicators of the endoscopy unit measured as the level of early warning score evaluations for patients was 95.97%±3.33, the level of cases where peripheral blood oxygen saturation decreased during sedation was 1.54%±3.78, the level of cases where patients experienced paradoxiical response during sedation was 5.82%±1.75, surveillance culturing level for validation of endoscopy reprocessing was 11.6%. The endoscopic documentation quality by peer review showed 95.7-100%, the colonoscopy quality indicators were followings as adenoma detection rate: 24.5% Cecal intubation rate: 99.1%, 95.2%, Colonoscope withdrawal average time: 13.28±10.62 minutes, Bowel preparation quality (Boston Scale): 89.3% 95.7%), patient discharge from the recovery room, Average discharge time post-procedure: With propofol alone: 30.92 minutes; With propofol and fentanyl combined: 31.52 minutes, The intermediate risk was 0.28% by the TROOPS evaluation during procedural sedation. Conclusion The quality benchmark levels for these endoscopic units, as determined by a single-center study, can be effectively implemented by benchmark endoscopy centers to enhance their quality and safety operations.

BackgroundThe preparations of multi-component have been the subject of chemical study for a long time. Therefore, when compounding the preparations of multi-component in traditional medicine, their taste is cautiously relied on, as the power of the one medicine should not be subdued with the power of another. Additionally the properties of the components and their regulating effects on the body systems are also considered. Our research group has been carrying out tests for raw materials,which are contained in multi-component preparations. However, it is a necessity to conduct phytochemical study on multi-component preparations in order to isolate pure biological active compounds and to identify their structure as well as to quantify its amount by modern techniques of analysis.GoalThe aim of the present study was to isolate pure biological active substances from Mongolian traditional medicine Garidi-5 and to elucidate their structures, which was used in Mongolian traditional medicine for the treatment of inflammation and as a pain relieving remedy.Objectives:1. To isolate pure substances from Garidi-5 and carry out tests to identify and determine their structure2. To quantify the amount of biological active substances.Materials and MethodsMongolian traditional medicine Garidi-5 has been selected as a biological natural product for the study. Garidi-5 is a traditional Mongolian medicine consisting of 5 medicinal herbs, namely Terminalia chebula Retz., Aconitum Kusnezoffii Reichb., Acorus calamus L., Saussurea lappa L., and musk of Moschus moschiferus and manufactured in the Drug factory of Traditional Medical Science Technology and Production Corporation of Mongolia. In this research, in order to determine the total content of phenolic compound was used the Folin–Ciocalteu method, which based on performing dark blue color complex compound. Isolated substance identification was determined by the TLC, UV and IR spectrophotometric methods. Inaddition it was checked melting point of the isolated substance. Determination of Gallic acid30g Garidi-5 was macerated in 60ml 80% methanol at room temperature for 24 h. After extraction, the extract was concentrated and vacuum evaporated. Different solvents from hexane, chloroform, ethyl acetate and n-butanol were used for theexperiment. All the extracts collected, evaporated and chromatographed on Silica gel column. Future purification of active fractions on Silica gel with methanol yielded the compound G1 which was further characterized as Gallic acid. Total phenolic content was determined spectrophotometrically according to the Folin–Ciocalteu’s method with slight modification. Gallic acid was used as a standard phenolic compound. Briefly, 1 ml of extract solution contains 1 mg extracts, in a volumetric flask diluted with distilled water (46 ml). One ml of Folin-Ciocalteu reagent was added and the content of the flask mixed thoroughly. After 3 min, 3 ml of Na2CO3 (2%) was added and then the mixture was allowed to stand for 2 h with intermittent shaking. The absorbance was measured at 760 nm in a spectrophotometer. All measurements were performed in triplicate.ResultsIn this research, TLC method on silica gel plates was used in order to identify the biological active pure substances from Garidi-5. Preliminary TLC experiments indicated the presence of Gallic acid in Garidi-5, which was isolated by column chromatography by comparing with reference standard substance (Gallic acid). Gallic acid was determined in the solvent system benzole-ethyl acetateformic acid- acetone (5:5:2:0.5) in isolated substance (G1). It showed blue color, Rf =0.65, on TLC plate. [1] For the characterization of two samples it was carried out IR analysis for each. In the IR spectra of G1 and standard substance can be recognized by the following absorption frequency regions: 700-900 cm-1 for Car-H; 1000-1300 cm-1 for vibration of bonds in various oxygen containing groups, 1350-1470 cm-1 for vibrations of –CH, -CH2 and –CH3 groups; 1500-1630 cm-1 for skeletal vibrations of aromatic rings, >C=O bonds; 2800-2950 cm-1 for stretching vibrations of –CH, -CH2 and -CH3 groups in saturated aliphatic structures; and 3030-3350 cm-1 for stretching associated vibrations of -OH groups in aromatic rings and aliphatic structures. As a result it was revealed that both IR spectra of G1 and standard substances were similar. [3]Further for the characterization of two samples it was carried out UV analysis of each. In the UV spectra of G1 and standard substance can be recognized by the following absorption frequency regions: 260-280nm for benzole groups; 200-225nm for carbonic acids; 400-770nm >C=O bonds, which reveal the presence of Gallic acid. In addition, melting point of isolated substance G1 was analyzed and detected at 2410C, which was similar to the standard substance’s melting point. [4]Moreover, Mongolian traditional medicine Garidi-5 contains 24% of the biological active substance (total phenolic compounds). [2]Conclusions:As a result of current study on Mongolian medicine Garidi-5, it was isolated one essential substance from ethyl acetate fraction. The phytochemical analysis reveals the presence of Gallic acid in Garidi- 5, which was determined by thin layer chromatography, UV and IR spectrophotometric methods. Mongolian traditional medicine Garidi-5 contains 24% of the biological active substance. Thus, the isolation of Gallic acid from multi-component preparations and identification of its structure was first phytochemical study conducted in our laboratory.